Clinical safety of the selective PKC-beta inhibitor, ruboxistaurin.
about
Activation of protein kinase C isoforms and its impact on diabetic complications.Activation of PKC isoform beta(I) at the blood-brain barrier rapidly decreases P-glycoprotein activity and enhances drug delivery to the brain.Novel Therapies for Diabetic Kidney Disease: Storied Past and Forward Paths.Redox control of renal function and hypertension.Ruboxistaurin: PKC-beta inhibition for complications of diabetes.Protein kinase C inhibitors: a patent review (2008 - 2009).
P2860
Clinical safety of the selective PKC-beta inhibitor, ruboxistaurin.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Clinical safety of the selective PKC-beta inhibitor, ruboxistaurin.
@ast
Clinical safety of the selective PKC-beta inhibitor, ruboxistaurin.
@en
type
label
Clinical safety of the selective PKC-beta inhibitor, ruboxistaurin.
@ast
Clinical safety of the selective PKC-beta inhibitor, ruboxistaurin.
@en
prefLabel
Clinical safety of the selective PKC-beta inhibitor, ruboxistaurin.
@ast
Clinical safety of the selective PKC-beta inhibitor, ruboxistaurin.
@en
P2093
P2860
P356
P1476
Clinical safety of the selective PKC-beta inhibitor, ruboxistaurin.
@en
P2093
David L Hyslop
Edward J Bastyr
George L King
Janet B McGill
Karen L Price
Keri A Kles
Paul H Berg
P2860
P304
P356
10.1517/14740338.5.6.835
P407
P577
2006-11-01T00:00:00Z